Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2026-02-26 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于子公司再次通过高新技术企业认定的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its subsidiaries receiving renewed high-tech enterprise certifications, which confer tax benefits. It includes details about the certificates, their validity, and the expected impact on the company's future financial performance. The document is short (774 characters) and does not contain any financial statements, detailed financial data, or comprehensive report content. It is an announcement of a regulatory or compliance nature related to tax status and certifications, not a full financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-02-26 Chinese
关于控股股东部分股份质押展期的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the extension of a pledge on shares held by a controlling shareholder. It details the number of shares pledged, the pledge period extension, and related shareholder information. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about share pledge extension, which fits best under the category of Regulatory Filings (RNS) as it does not fit other more specific categories like Major Shareholding Notification (MRQ) or Transaction in Own Shares (POS). The document length is short and it is a formal disclosure of a shareholder's pledge extension.
2026-02-12 Chinese
关于重酒石酸去甲肾上腺素注射用浓溶液获得新加坡注册批文的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about receiving a new drug registration approval from the Singapore Health Sciences Authority (HSA). It details the product name, registration number, and the significance of this approval for the company. The document is short (1017 characters) and serves as a formal public announcement of a regulatory milestone rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed regulatory filings like audit reports or annual reports. It is not a report publication announcement since it does not mention the release of a report but rather announces a regulatory approval. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-02-06 Chinese
关于在下属子公司之间调剂担保额度及为全资子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 亿帆医药股份有限公司 regarding the adjustment and provision of guarantee limits among its subsidiaries. It details the internal reallocation of guarantee amounts, the signing of a guarantee contract with a bank, and the approval status from the board and shareholders. The document includes financial figures related to guarantees but does not contain comprehensive financial statements or detailed financial performance data. It is an update on financing-related activities, specifically about guarantees and credit limits, rather than a full financial report or earnings release. The document length is 3710 characters, which is relatively short and typical for an announcement. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company financing activities and capital structure changes such as guarantees and credit arrangements.
2026-02-03 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about receiving a drug registration certificate from the national drug regulatory authority. It details the certificate information, product description, and potential impact on the company. It is not a financial report, earnings release, or management discussion. It is a regulatory announcement about a product approval, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2026-02-02 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from a pharmaceutical company about receiving a drug registration certificate from the national drug regulatory authority. It details the certificate information, product description, and potential impact on the company. The document is short (1055 characters) and serves as a regulatory announcement rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or other report content. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-01-23 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.